Vertex Pharmaceuticals Incorporated $VRTX Stock Purchased by Provenance Wealth Advisors LLC

Key Points

• Provenance Wealth Advisors increased its Vertex stake by 20,080% in the third quarter, to 2,018 shares valued at about $1.055 million; institutional investors own roughly 91% of the stock.
• Vertex reported quarterly revenue of $3.44 billion, up 11.8% year over year and ahead of estimates, but earnings of $4.76 per share fell short of the $4.82 consensus.
• Analyst sentiment remains broadly positive: Vertex has a “Moderate Buy” consensus rating and an average price target of $596.44, with 25 analysts rating it Buy and two rating it Hold.

Provenance Wealth Advisors LLC lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 20,080.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,018 shares of the pharmaceutical company's stock after buying an additional 2,008 shares during the quarter. Provenance Wealth Advisors LLC's holdings in Vertex Pharmaceuticals were worth $1,055,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Summit Global Investments purchased a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at about $3,568,000. Calamos Advisors LLC grew its stake in Vertex Pharmaceuticals by 77.1% in the 1st quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company's stock worth $34,779,000 after acquiring an additional 33,917 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth about $13,823,000. UNIVEST FINANCIAL Corp bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth about $4,495,000. Finally, Meeder Advisory Services Inc. purchased a new position in shares of Vertex Pharmaceuticals during the second quarter worth approximately $3,187,000. 90.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VRTX. Leerink Partners started coverage on shares of Vertex Pharmaceuticals in a research note on Monday, September 21st. They set an "outperform" rating and a $594.00 price target for the company. The Goldman Sachs Group increased their price objective on Vertex Pharmaceuticals from $654.00 to $725.00 and gave the stock a "buy" rating in a research note on Tuesday. Evercore increased their price objective on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 2nd. UBS Group raised their price objective on Vertex Pharmaceuticals from $615.00 to $640.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, TD Cowen lifted their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a "buy" rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $596.44.

Vertex Pharmaceuticals Stock Up 3.4%

Shares of Vertex Pharmaceuticals stock opened at $549.04 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 2.74. Vertex Pharmaceuticals Incorporated has a 1 year low of $406.67 and a 1 year high of $568.67. The firm's 50-day moving average is $522.90 and its two-hundred day moving average is $480.92. The stock has a market cap of $139.35 billion, a price-to-earnings ratio of 35.33, a PEG ratio of 2.56 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The business had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the firm posted $4.80 EPS. The company's revenue for the quarter was up 11.8% compared to the same quarter last year. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 16.64 earnings per share for the current fiscal year.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up 12% year over year and ahead of estimates, with cystic fibrosis medicines and newer products including CASGEVY and JOURNAVX contributing. The company raised its 2026 revenue outlook, while management highlighted the potential for povetacicept, which faces an FDA decision for IgA nephropathy on November 30. Vertex Q3 2026 earnings call highlights
• Positive Sentiment: Analyst actions have generally been supportive: Barclays raised its price target to $626 and kept an overweight rating, while H.C. Wainwright reiterated Buy and TD Cowen also rated the shares Buy. These endorsements may bolster confidence in Vertex’s growth prospects.
• Neutral Sentiment: Investors are also focused on Vertex’s efforts to expand beyond cystic fibrosis into kidney and rare endocrine diseases—potential future growth drivers, but ones that will take time to establish. Vertex: 3 key takeaways for long-term investors
• Negative Sentiment: Quarterly earnings per share came in below analyst expectations, and acquisition costs weighed on profit. Reports also pointed to lighter-than-hoped-for sales of the pain drug JOURNAVX, contributing to a selloff after the earnings release. Vertex slumps on light pain drug sales

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.